Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management

IF 3 3区 医学 Q2 ONCOLOGY
Roelof W.F. van Leeuwen , Marianne le Comte , Anna K.L. Reyners , Annemieke van den Tweel , Bas van Vlijmen , Wilma Kwee , Brigit Wensveen , Neeltje Steeghs , Otto Visser , Teun van Gelder , Frank G.A. Jansman
{"title":"Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management","authors":"Roelof W.F. van Leeuwen ,&nbsp;Marianne le Comte ,&nbsp;Anna K.L. Reyners ,&nbsp;Annemieke van den Tweel ,&nbsp;Bas van Vlijmen ,&nbsp;Wilma Kwee ,&nbsp;Brigit Wensveen ,&nbsp;Neeltje Steeghs ,&nbsp;Otto Visser ,&nbsp;Teun van Gelder ,&nbsp;Frank G.A. Jansman","doi":"10.1053/j.seminoncol.2022.03.002","DOIUrl":null,"url":null,"abstract":"<div><p>Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch Multidisciplinary Expert group is assessing the clinical significance of DDIs in oncology and provides recommendations for the management of these DDIs. We present an overview of methodology and outcome of an evidence- and consensus-based assessment of DDIs between anticancer drugs and non-anticancer drugs.</p><p>A literature search was performed through PubMed and EMA and FDA assessment reports, to identify potential DDI's involving anticancer drugs. For each potential DDI a concept report for risk analysis and practical advice for management was created. Subsequently, this risk analysis and the corresponding advice were assessed and weighed.</p><p>A total of 290 potential DDIs have been identified in the literature thus far. Of these 290 potential DDIs, the Expert Group has identified 94 (32%) DDIs as clinically relevant, with a need for an automated alert and a suggested intervention. Furthermore, 110 DDIs have been identified as clinically not relevant. For 86 potential DDIs evidence supporting a relevant DDI was insufficient and in these cases neither an alert nor advice regarding a suggested intervention were formulated.</p><p>A transparent risk analysis is presented for identification of clinically relevant DDIs with anticancer drugs. Integration of DDI guidelines into the national electronic prescribing system is essential to achieve optimal efficacy and minimal toxicity in patients receiving anticancer therapy. A clear overview of clinically relevant DDIs with anticancer therapy provides clinicians with a structured, evidence-based and consensus-built tool for anticancer therapy surveillance.</p></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0093775422000239/pdfft?md5=1fdc9c2fa011b2569e5c79eb7e798922&pid=1-s2.0-S0093775422000239-main.pdf","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775422000239","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 7

Abstract

Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch Multidisciplinary Expert group is assessing the clinical significance of DDIs in oncology and provides recommendations for the management of these DDIs. We present an overview of methodology and outcome of an evidence- and consensus-based assessment of DDIs between anticancer drugs and non-anticancer drugs.

A literature search was performed through PubMed and EMA and FDA assessment reports, to identify potential DDI's involving anticancer drugs. For each potential DDI a concept report for risk analysis and practical advice for management was created. Subsequently, this risk analysis and the corresponding advice were assessed and weighed.

A total of 290 potential DDIs have been identified in the literature thus far. Of these 290 potential DDIs, the Expert Group has identified 94 (32%) DDIs as clinically relevant, with a need for an automated alert and a suggested intervention. Furthermore, 110 DDIs have been identified as clinically not relevant. For 86 potential DDIs evidence supporting a relevant DDI was insufficient and in these cases neither an alert nor advice regarding a suggested intervention were formulated.

A transparent risk analysis is presented for identification of clinically relevant DDIs with anticancer drugs. Integration of DDI guidelines into the national electronic prescribing system is essential to achieve optimal efficacy and minimal toxicity in patients receiving anticancer therapy. A clear overview of clinically relevant DDIs with anticancer therapy provides clinicians with a structured, evidence-based and consensus-built tool for anticancer therapy surveillance.

基于证据和共识的药物与抗癌药物相互作用指南;一个实用和通用的管理工具
药物-药物相互作用(ddi)与抗癌药物是常见的,并能显著影响治疗的疗效和毒性。因此,一个荷兰多学科专家组正在评估ddi在肿瘤学中的临床意义,并为这些ddi的管理提供建议。我们概述了基于证据和共识的抗癌药物和非抗癌药物之间ddi评估的方法和结果。通过PubMed、EMA和FDA的评估报告进行文献检索,以确定涉及抗癌药物的潜在DDI。为每个潜在的DDI创建了一份概念报告,用于风险分析和管理方面的实际建议。随后,对风险分析和相应的建议进行评估和权衡。迄今为止,文献中已确定了290个潜在的发展中国家。在这290个潜在的ddi中,专家组确定了94个(32%)ddi与临床相关,需要自动警报和建议干预。此外,110例ddi已被确定为与临床无关。对于86例潜在的DDI,支持相关DDI的证据不足,在这些病例中,既没有就建议的干预措施提出警告,也没有提出建议。一个透明的风险分析提出了鉴别临床相关的ddi与抗癌药物。将DDI指南整合到国家电子处方系统中对于在接受抗癌治疗的患者中实现最佳疗效和最小毒性至关重要。临床相关ddi与抗癌治疗的清晰概述为临床医生提供了一个结构化的、基于证据的、建立共识的抗癌治疗监测工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Seminars in oncology
Seminars in oncology 医学-肿瘤学
CiteScore
6.60
自引率
0.00%
发文量
58
审稿时长
104 days
期刊介绍: Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信